Other CAR T targets under clinical evaluation include EGFR [NCT02980315], MUC1 [NCT03013712], CD44v6 [NCT04729543, NCT04097301], PD-L1 [NCT05117138], and CSPG4 [NCT06096038], reflecting efforts to overcome tumor heterogeneity and immune evasion. The gene discussed is EGFR; the disease is neoplasm.